230 related articles for article (PubMed ID: 23918871)
1. Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer.
Zagon IS; Porterfield NK; McLaughlin PJ
Exp Biol Med (Maywood); 2013 Jun; 238(6):589-99. PubMed ID: 23918871
[TBL] [Abstract][Full Text] [Related]
2. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS; Donahue R; McLaughlin PJ
Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
[TBL] [Abstract][Full Text] [Related]
3. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
4. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
[TBL] [Abstract][Full Text] [Related]
5. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
[TBL] [Abstract][Full Text] [Related]
7. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
Donahue RN; McLaughlin PJ; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
[TBL] [Abstract][Full Text] [Related]
8. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
[TBL] [Abstract][Full Text] [Related]
9. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer.
Cheng F; McLaughlin PJ; Verderame MF; Zagon IS
Mol Cancer; 2008 Jan; 7():5. PubMed ID: 18190706
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
Kren NP; Zagon IS; McLaughlin PJ
Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
[TBL] [Abstract][Full Text] [Related]
12. Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis.
Campbell AM; Zagon IS; McLaughlin PJ
Brain Res Bull; 2013 Jan; 90():43-51. PubMed ID: 22985690
[TBL] [Abstract][Full Text] [Related]
13. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor.
McLaughlin PJ; Zagon IS
Int J Oncol; 2006 Jun; 28(6):1577-83. PubMed ID: 16685459
[TBL] [Abstract][Full Text] [Related]
14. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
[TBL] [Abstract][Full Text] [Related]
15. Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking.
Cheng F; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2010 Sep; 235(9):1093-101. PubMed ID: 20705629
[TBL] [Abstract][Full Text] [Related]
16. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
Zagon IS; Donahue RN; McLaughlin PJ
Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1154-61. PubMed ID: 19675283
[TBL] [Abstract][Full Text] [Related]
17. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
Zagon IS; McLaughlin PJ
Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis.
Klocek MS; Sassani JW; Donahue RN; McLaughlin PJ; Zagon IS
Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5054-61. PubMed ID: 20463323
[TBL] [Abstract][Full Text] [Related]
19. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.
Avella DM; Kimchi ET; Donahue RN; Tagaram HR; McLaughlin PJ; Zagon IS; Staveley-O'Carroll KF
Am J Physiol Regul Integr Comp Physiol; 2010 Feb; 298(2):R459-66. PubMed ID: 19923357
[TBL] [Abstract][Full Text] [Related]
20. Novel treatment for triple-negative breast and ovarian cancer: endogenous opioid suppression of women's cancers.
McLaughlin PJ; Zagon IS
Expert Rev Anticancer Ther; 2014 Mar; 14(3):247-50. PubMed ID: 24397732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]